SequelSEC

Processa Pharmaceuticals, Inc. PCSA

Pharmaceutical Preparations · CIK 0001533743 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2022-12-31
Operating income
-$27.53M
Fiscal year ended 2022-12-31
Free cash flow
Unavailable
Fiscal year ended 2022-12-31

Processa Pharmaceuticals, Inc. (PCSA) reported revenue of $0 and net income of -$27.42M for the fiscal year ended 2022-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Processa Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Processa Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312016-12-312015-12-312014-12-31
Revenue$0$0$5.00K$113.42K$107.24K
Cost of revenueUnavailableUnavailableUnavailable$125.88K$66.83K
Gross profitUnavailableUnavailable$5.00K-$12.45K$40.41K
Operating income-$27.53M-$12.13M-$1.92MUnavailableUnavailable
Net income-$27.42M-$11.43M-$1.92M-$3.35M-$4.53M
Research & development$11.49M$6.88M$1.54M$29.25K$178.08K
Weighted-average diluted sharesUnavailableUnavailableshares 29.32MUnavailableUnavailable
Pretax income-$27.42M-$11.96M-$337.18K-$2.98M-$3.69M
Income tax expenseUnavailable-$530.61KUnavailable-$100-$100
Diluted EPS$-34.05Unavailable$-0.07UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailable$69.97K$945.46K$2.02M
General & administrative$8.76M$4.69MUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Processa Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312016-12-312015-12-312014-12-31
Cash & equivalents$6.50M$16.50M$1.07M$2.09K$21.23K
Total assets$8.62M$26.46M$2.36M$104.32K$2.55M
Current assets$8.39M$18.33M$2.34M$104.16K$383.02K
Total liabilities$1.15M$978.40K$97.69K$2.08M$1.34M
Current liabilities$998.56K$971.02K$97.69K$2.08M$843.86K
Total equity incl. NCI$7.47M$25.49M-$2.27M-$85.70K$1.21M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable$219.20K
Accounts receivableUnavailableUnavailableUnavailableUnavailable$1.31K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$327.55K$218.90K$14.59K$159.25K$153.93K

Cash flow

Processa Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312016-12-312015-12-312014-12-31
Operating cash flow-$9.61M-$8.72M-$2.16M-$871.91K-$2.69M
Capital expendituresUnavailableUnavailable$23.78K$1.40K$11.01K
Investing cash flowUnavailableUnavailable-$1.04M$40.20K-$44.94K
Financing cash flow-$388.84K$9.80M$4.27M$821.10K$2.57M
Net change in cash-$9.99M$1.08M$1.07M-$10.60K-$161.82K
Stock-based compensation$8.83M$3.41M$6.69K$96.93K$231.52K
Common dividends paidUnavailableUnavailableUnavailable$42.94K$45.59K
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Processa Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312016-12-312015-12-312014-12-31
Free cash flowUnavailableUnavailable-$2.18M-$873.30K-$2.70M
Gross marginUnavailableUnavailable100.0%-11.0%37.7%
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable-769.9%-2520.2%
SBC / revenueUnavailableUnavailable133.8%85.5%215.9%
Current ratio8.40x18.87x23.92x0.05x0.45x
Revenue YoY growthUnavailableUnavailable-95.6%5.8%Unavailable
Net marginUnavailableUnavailableUnavailable-2957.2%-4220.7%
R&D / revenueUnavailableUnavailableUnavailable25.8%166.1%
CapEx / revenueUnavailableUnavailableUnavailable1.2%10.3%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PCSA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-18View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2016-12-31

Difference 4534458 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2015-12-31

Difference 1893102 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.